The future of chronic lymphocytic leukemia: potential directions from ASH 2017.
Novel targeted therapies - including ibrutinib, venetoclax, and idelalisib - have revolutionized the treatment landscape of chronic lymphocytic leukemia (CLL). Therefore, studying combinations of novel agents (NAs) with a distinct mechanism of action and nonoverlapping toxicities is challenging. Area covered: The 2017 American Society Hematology Annual Meeting has represented a showcase for several trials combining NAs. These studies are currently evaluating the efficacy NA plus anti-CD20 monoclonal antibody, NA plus NA (with or without anti-CD20 monoclonal antibody), and NA plus chemo-immunotherapy. Expert commentary: The development of well-tolerated, highly effective combination strategies with curative potential for patients with CLL is becoming a realistic goal in CLL. From a practical standpoint, it is hard to determine which regimen will be most beneficial. Until studies of association will provide more mature results, the sequencing of NA remains a reasonable approach.